PRKCD and cancer: These findings suggestthat the PKC-δ C2 domain can be viewed as a pharmacologicaltool to modulate cancer cell behavior and could be explored therapeutically.Furthermore, this study provides experimental evidence that a regulatorydomain of PKC-δ can influence apoptotic and stress-responsepathways, highlighting a previously underappreciated layer of kinaseregulation.